Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib

The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis

(2016) Darryl P. Leong et al.   BLOOD

Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL)

(2016) Tait D. Shanafelt et al.   LEUKEMIA & LYMPHOMA

Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study

(2015) J. Donato et al.   BLOOD

Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

(2015) Jan A. Burger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

(2014) J. R. McMullen et al.   BLOOD

2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation

(2014) Craig T. January et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Ibrutinib inhibits collagen-mediated but not ADP-mediated platelet aggregation

(2014) S Kamel et al.   LEUKEMIA

European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation

(2013) Hein Heidbuchel et al.   EUROPACE

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

An Updated Review of Target‐Specific Oral Anticoagulants Used in Stroke Prevention in Atrial Fibrillation, Venous Thromboembolic Disease, and Acute Coronary Syndromes

(2013) Christina L. Cove et al.   Journal of the American Heart Association